Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/346"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:content |
"The FDA lists this as a "strong" CYP2C19 inhibitor in its most recent guidance document. See Tables 2, p19 and 6, p. 23.
NOTE: there is no mention of omeprazole as a recommended or acceptable in vitro inhibitor in Table 2, p28"
|
| dc:creator | |
| dc:date |
"06/12/2009 13:29:15"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ omeprazole_in_vitro_selective_inhibitor_of_enzyme_cyp2c19, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1815 }